Press ReleaseView printer-friendly version << Back
vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update
Paul Sekhriappointed as President, Chief Executive Officer and Board member.
- Entered into agreements with CinRx Pharma and a subsidiary to purchase
$10 millionin stock and to leverage CinRx’s industry experience to collaborate in overseeing TTP399 clinical trials.
- Entered into agreements with G42 Investments to purchase
$25 millionin stock, collaborate on clinical trials and exclusively license rights to develop and commercialize TTP399 in certain geographic markets by a G42 affiliate.
“I have been with vTv for only about two weeks but the strategic steps that have been taken toward initiating the TTP399 pivotal study and the energy displayed by the team to execute on that program have been truly impressive,” said
- Leadership. On
July 27, 2022, the Company appointed Paul Sekhrias President, Chief Executive Officer (CEO) effective August 1, 2022, and was confirmed as a member of the board of directors on August 9, 2022. Mr. Sekhribrings nearly 30 years of healthcare industry experience, including serving as President and CEO of several healthcare companies, experience in several senior business development and strategy roles and he has been a director on more than 30 private, public company and non-profit boards.
- Partnership. On
July 25, 2002, the Company entered into agreements with CinRx Pharma and its subsidiary, CinPax. CinPax agreed to acquire $10.0 millionin vTv Class A common stock at approximately $2.41per share with $6.0 millionpaid at closing and the remaining $4.0 millionpayable on November 22, 2022. vTv will issue a warrant to CinRx to acquire 1.2 million additional shares of Class A common stock at an exercise price of approximately $0.72per share that will become exercisable upon agreed vesting triggers. In addition, the agreements set forth terms under which vTv will leverage the CinRx team’s industry experience to collaborate on the oversight of the clinical trials for pharmaceutical products that contain TTP399.
- Publication. In June, results of a Phase 1 trial that assessed the effects of TTP399 on ketoacidosis risk in individuals with T1D on insulin pump therapy during acute insulin withdrawal was published in Diabetes Obesity and Metabolism (https://doi.org/10.1111/dom.14697) and presented at The
American Diabetes Association's82nd Scientific Sessions on June 5, 2022. The results suggested that TTP399 does not increase, and may decrease, the risk of diabetic ketoacidosis (DKA) in subjects with T1D.
- Partnership. On
May 31, 2022, the Company entered into agreements with G42 Healthcare("G42") and an affiliate. G42 agreed to acquire $25.0 millionin vTv Class A common stock at approximately $2.41per share with $12.5 millionpaid at closing and the remaining $12.5 millionpayable on May 31, 2023. The agreements also provide for the potential issuance of $30.0 millionin additional shares of Class A common stock to G42 (or cash in lieu of such issuance at the option of G42) if the U.S. Food and Drug Administration(FDA) approves the marketing and sale of a pharmaceutical product containing TTP399. vTv and an affiliate of G42 plan to collaborate on clinical trials for pharmaceutical products that contain TTP399, including G42’s affiliate funding a portion of the Phase 3 clinical trials for TTP399, and vTv granting G42’s affiliate an exclusive license to develop and commercialize pharmaceutical products containing TTP399 in certain territories in the Middle East, Africa, and Central Asia.
Upcoming Milestones and Events
- Pivotal Study Planning. The Company is planning two pivotal, placebo-controlled clinical trials of TTP399 in subjects with T1D and has engaged with the FDA on the optimal clinical trial designs for these studies. The studies will recruit a total of approximately 1,000 patients and at least one of the studies will be one year of treatment. The FDA and the Company have agreed on the primary endpoint for the studies as the difference between placebo and TTP399-treated group in number of hypoglycemia events. These pivotal studies are expected to start in the fourth quarter of 2022.
Second Quarter 2022 Financial Results
- Cash Position: The Company’s cash position as of
June 30, 2022, was $17.9 millioncompared to $13.4 millionas of December 31, 2021.
- Research & Development (R&D) Expenses: R&D expenses were
$2.2 millionand $2.4 millionin each of the three months ended June 30, 2022, and 2021, respectively. The decrease of $0.2 millionis attributable to a decrease in clinical trial costs for azeliragon, which was mainly driven by discontinuance of its development as a potential treatment of Alzheimer’s disease in patients with type 2 diabetes and a decrease in spending related to a multiple ascending dose study for HPP737, due to its completion in 2021, offset by higher spending on TTP399 due to trial preparation costs.
- General & Administrative (G&A) Expenses: G&A expenses were
$1.8 millionand $2.2 millionfor each of the three months ended June 30, 2022, and 2021, respectively. The decrease was due to lower payroll costs and lower share-based expense partially offset by higher legal expense and higher other G&A costs.
- Other (Expense)/Income: Other expense for the three months ended
June 30, 2022, was $0.1 millionand was driven by an unrealized loss related to the investment in Reneo as well as the gains related to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to a related party (“Related Party Warrants”). Other income for the three months ended June 30, 2021, was $3.8 millionand was related to the unrealized gain recognized related to the investment in Reneo as well as gains related to the change in the fair value of the outstanding warrants in our own stock held by a related party.
- Net Loss: Net loss attributable to vTv shareholders for the three months ended
June 30, 2022, was $3.2 millionor $0.04per basic share. Net loss attributable to vTv shareholders for the comparable period a year ago was $0.6 millionor $0.01per basic share.
Condensed Consolidated Balance Sheets
|Cash and cash equivalents||$||17,863||$||13,415|
|Promissory note receivable||11,941||—|
|Prepaid expenses and other current assets||643||2,049|
|Total current assets||30,609||15,621|
|Property and equipment, net||254||278|
|Operating lease right-of-use assets||354||402|
|Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Deficit|
|Accounts payable and accrued expenses||$||9,600||$||8,023|
|Current portion of operating lease liabilities||199||184|
|Current portion of contract liabilities||26||35|
|Current portion of notes payable||—||256|
|Total current liabilities||9,825||8,498|
|Contract liabilities, net of current portion||18,669||—|
|Operating lease liabilities, net of current portion||388||492|
|Warrant liability, related party||717||1,262|
|Commitments and contingencies|
|Redeemable noncontrolling interest||15,916||24,962|
|Class A Common Stock||773||669|
|Class B Common Stock||232||232|
|Additional paid-in capital||243,772||238,193|
|Total stockholders’ deficit attributable to
|Total liabilities, redeemable noncontrolling interest and stockholders’ deficit||$||36,989||$||25,474|
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
|Three Months Ended
||Six Months Ended
|Research and development||2,205||2,437||5,338||5,540|
|General and administrative||1,831||2,242||7,179||4,406|
|Total operating expenses||4,036||4,679||12,517||9,946|
|Other (expense) income, net||(114||)||3,829||(2,856||)||2,181|
|Loss before income taxes||(4,091||)||(841||)||(13,315||)||(6,768||)|
|Income tax provision||—||—||200||15|
|Net loss before noncontrolling interest||(4,091||)||(841||)||(13,515||)||(6,783||)|
|Less: Net loss attributable to noncontrolling interest||(940||)||(233||)||(3,357||)||(1,934||)|
|Net loss attributable to
|Net loss attributable to
|Net loss per share of
|Weighted average number of
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the
Source: vTv Therapeutics Inc.